Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Dianthus Therapeutics, Inc. (DNTH)

82.38 -0.32 (-0.39%)
At close: 4:00:01 PM EDT
82.38 0.00 (0.00%)
After hours: 4:00:16 PM EDT
Trade DNTH on Coinbase
Chart Range Bar
Loading chart for DNTH
  • Previous Close 82.70
  • Open 81.29
  • Bid 59.17 x 200
  • Ask 103.52 x 200
  • Day's Range 80.63 - 83.73
  • 52 Week Range 32.28 - 117.88
  • Volume 496,892
  • Avg. Volume 822,371
  • Market Cap (intraday) 4.503B
  • Beta (5Y Monthly) 0.18
  • PE Ratio (TTM) --
  • EPS (TTM) -4.24
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 139.06
  • Zacks Rating Neutral

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

dianthustx.com

92

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DNTH
99.90%
S&P 500 (^GSPC)
10.73%

1-Year Return

DNTH
144.16%
S&P 500 (^GSPC)
11.11%

3-Year Return

DNTH
588.22%
S&P 500 (^GSPC)
81.91%

5-Year Return

DNTH
19.55%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 761k
Earnings -50.22M
Profit Margin -6,598.55%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-60M
-40M
-20M
0
-20000.0%
-15000.0%
-10000.0%

Analyst Insights

View More

Analyst Price Targets

113.00
139.06 Average
82.38 Current
200.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/27/2026
Analyst Roth Capital
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 113

Statistics

View More

Valuation Measures

Annual
As of 10/29/2026
  • Market Cap

    4.63B

  • Enterprise Value

    3.74B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    2.02k

  • Price/Book (mrq)

    3.85

  • Enterprise Value/Revenue

    1.96k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -17.69%

  • Return on Equity (ttm)

    -26.07%

  • Revenue (ttm)

    1.9M

  • Net Income Avi to Common (ttm)

    -192.25M

  • Diluted EPS (ttm)

    -4.24

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    886.81M

  • Total Debt/Equity (mrq)

    0.11%

  • Levered Free Cash Flow (ttm)

    -92.21M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

82.38 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: